CHINOOK THERAPEUTICS INC's ticker is KDNY and the CUSIP is 16961L106. A total of 158 filers reported holding CHINOOK THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.03 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $166,956,377 | +66.0% | 4,345,559 | 0.0% | 9.97% | +36.9% |
| Q1 2023 | $100,599,691 | -11.6% | 4,345,559 | 0.0% | 7.28% | +2.9% |
| Q4 2022 | $113,853,646 | +35.8% | 4,345,559 | +1.9% | 7.08% | +9.6% |
| Q3 2022 | $83,861,000 | +33.4% | 4,265,559 | +18.7% | 6.46% | +8.8% |
| Q2 2022 | $62,877,000 | +41.7% | 3,595,026 | +32.6% | 5.93% | +56.9% |
| Q1 2022 | $44,369,000 | – | 2,712,041 | – | 3.78% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 5,161,888 | $135,241,466 | 29.11% |
| Octagon Capital Advisors LP | 2,551,703 | $66,854,619 | 10.41% |
| Affinity Asset Advisors, LLC | 818,035 | $21,432,517 | 8.40% |
| Frazier Life Sciences Management, L.P. | 4,345,559 | $113,853,646 | 7.08% |
| Saturn V Capital Management LP | 423,177 | $6,728,298 | 5.58% |
| Altium Capital Management LP | 385,000 | $10,087,000 | 5.13% |
| Deep Track Capital, LP | 3,000,000 | $78,600,000 | 3.30% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 340,389 | $8,914,788 | 2.75% |
| Vivo Capital, LLC | 872,151 | $22,850 | 2.63% |
| Nan Fung Group Holdings Ltd | 113,950 | $2,985,490 | 2.06% |